You might be interested in…ADHD

Mental Health , 0 Comments

Discovering the Latest Clinical Studies on Attention-deficit Hyperactivity Disorder (ADHD) with Dr. Ray O'Connor




Attention-deficit hyperactivity disorder (ADHD) is a prevalent neurodevelopmental condition affecting both children and adults. Individuals with ADHD face increased risks, including premature death due to unnatural causes.




Dr Ray O'Connor

Dr Ray O’Connor




A recent observational cohort study in Sweden investigated the impact of ADHD pharmacotherapy on reducing all-cause mortality risk in individuals diagnosed with ADHD. The study revealed a lower mortality risk in individuals who initiated ADHD medication, particularly for deaths due to unnatural causes.



Global estimates of ADHD prevalence vary across studies, with factors such as diagnostic criteria and sampling methods influencing the reported rates. Parenting and family environment have been identified as significant factors influencing ADHD symptoms in children.



Research on ADHD medications for adults highlights the need for safer and more efficacious treatments. While ongoing clinical trials show promise, more effective options are required to address the diverse needs of adults with ADHD.



Metabolomics research aims to identify biomarkers for precise ADHD diagnosis and targeted interventions. While no simple blood test is currently available, metabolic signatures related to neurotransmitter dysregulation and stress pathways show potential for future diagnostic advancements.



References:



  1. Li L et al. ADHD Pharmacotherapy and Mortality in Individuals With ADHD. JAMA 2024 Mar 12;331(10):850–860. doi: 10.1001/jama.2024.0851

  2. Popit S et al. Prevalence of attention-deficit hyperactivity disorder (ADHD): systematic review and meta-analysis. European Psychiatry 2024, 67(1), e68, 1–23 https://doi.org/10.1192/j.eurpsy.2024.1786

  3. Claussen A et al. All in the Family? A Systematic Review and Meta‑analysis of Parenting and Family Environment as Risk Factors for Attention‑Deficit/Hyperactivity Disorder (ADHD) in Children. Prevention Science 2022 https://doi.org/10.1007/s11121-022-01358-4

  4. Veronesi G et al. Treatments in the pipeline for attention-deficit/hyperactivity disorder (ADHD) in adults. Neurosci Biobehav Rev 2024 Aug:163:105774. doi: 10.1016/j.neubiorev.2024.105774 Epub 2024 Jun 22.

  5. Predescu E et al. Metabolomic Markers in Attention-Deficit/Hyperactivity Disorder (ADHD) among Children and Adolescents—A Systematic Review. Int. J. Mol. Sci. 2024, 25, 4385. https://doi.org/10.3390/ijms25084385

Author